139 related articles for article (PubMed ID: 33826473)
41. Use of third-line therapies in advanced sarcoidosis.
Lower EE; Sturdivant M; Grate L; Baughman RP
Clin Exp Rheumatol; 2020; 38(5):834-840. PubMed ID: 31820728
[TBL] [Abstract][Full Text] [Related]
42. Acthar® Gel (repository corticotropin injection) dose-response relationships in an animal model of epileptic spasms.
Le JT; Frost JD; Swann JW
Epilepsy Behav; 2021 Mar; 116():107786. PubMed ID: 33548914
[TBL] [Abstract][Full Text] [Related]
43. Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series.
Brown AN
Open Access Rheumatol; 2016; 8():97-102. PubMed ID: 27956846
[TBL] [Abstract][Full Text] [Related]
44. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
45. Repository corticotropin injection (H.P. Acthar gel) for the treatment of sarcoidosis-induced hypercalciuria and vitamin D dysregulation: a pilot, open label study.
Judson MA; Modi A; Ilyas F; Yucel R
Sarcoidosis Vasc Diffuse Lung Dis; 2018; 35(3):192-197. PubMed ID: 32476902
[No Abstract] [Full Text] [Related]
46. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids.
Wynn D; Goldstick L; Bauer W; Zhao E; Tarau E; Cohen JA; Robertson D; Miller A
CNS Neurosci Ther; 2022 Mar; 28(3):364-371. PubMed ID: 34984839
[TBL] [Abstract][Full Text] [Related]
47. Distinguishing Features of Ocular Sarcoidosis in an International Cohort of Uveitis Patients.
Acharya NR; Browne EN; Rao N; Mochizuki M;
Ophthalmology; 2018 Jan; 125(1):119-126. PubMed ID: 28823384
[TBL] [Abstract][Full Text] [Related]
48. [Ocular and neuro-ophthalmic manifestations of sarcoidosis: retrospective study of 30 cases].
Bezo C; Majzoub S; Nochez Y; Leruez S; Charlin JF; Milea D; Pisella PJ
J Fr Ophtalmol; 2013 Jun; 36(6):473-80. PubMed ID: 23545336
[TBL] [Abstract][Full Text] [Related]
49. Uveitis in sarcoidosis.
Uyama M
Int Ophthalmol Clin; 2002; 42(1):143-50. PubMed ID: 12189610
[TBL] [Abstract][Full Text] [Related]
50. Treatment of Noninfectious Retinal Vasculitis Using Subcutaneous Repository Corticotropin Injection.
Anesi SD; Chang PY; Maleki A; Stephenson A; Montieth A; Filipowicz A; Syeda S; Asgari S; Walsh M; Metzinger JL; Foster CS
J Ophthalmic Vis Res; 2021; 16(2):219-233. PubMed ID: 34055260
[TBL] [Abstract][Full Text] [Related]
51. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS).
Herbort CP; Rao NA; Mochizuki M;
Ocul Immunol Inflamm; 2009; 17(3):160-9. PubMed ID: 19585358
[TBL] [Abstract][Full Text] [Related]
52. Long-term visual and systemic prognoses of 83 cases of biopsy-proven sarcoid uveitis.
Rochepeau C; Jamilloux Y; Kerever S; Febvay C; Perard L; Broussolle C; Burillon C; Kodjikian L; Seve P
Br J Ophthalmol; 2017 Jul; 101(7):856-861. PubMed ID: 27888183
[TBL] [Abstract][Full Text] [Related]
53. Sarcoidosis-related Uveitis: Clinical Presentation, Disease Course, and Rates of Systemic Disease Progression After Uveitis Diagnosis.
Ma SP; Rogers SL; Hall AJ; Hodgson L; Brennan J; Stawell RJ; Lim LL
Am J Ophthalmol; 2019 Feb; 198():30-36. PubMed ID: 30243930
[TBL] [Abstract][Full Text] [Related]
54. Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study.
Rahaghi FF; Sweiss NJ; Saketkoo LA; Scholand MB; Barney JB; Gerke AK; Lower EE; Mirsaeidi M; O'Hare L; Rumbak MJ; Samavati L; Baughman RP
Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32198219
[TBL] [Abstract][Full Text] [Related]
55. Prognosis Factors and Outcomes of Neuro-ophthalmologic Sarcoidosis.
Leclercq M; Sené T; Chapelon-Abric C; Desbois AC; Domont F; Maillart E; Shor N; Vignal-Clermont C; Guéguen A; Bodaghi B; Cacoub P; Touitou V; Saadoun D
Ocul Immunol Inflamm; 2022 May; 30(4):821-828. PubMed ID: 33166196
[TBL] [Abstract][Full Text] [Related]
56. Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action.
Gillis T; Crane M; Hinkle C; Wei N
Open Access Rheumatol; 2017; 9():131-138. PubMed ID: 28790870
[TBL] [Abstract][Full Text] [Related]
57. A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus.
Askanase AD; Furie RA
Adv Ther; 2022 Jul; 39(7):3088-3103. PubMed ID: 35641860
[TBL] [Abstract][Full Text] [Related]
58. Progress in the diagnosis of ocular sarcoidosis.
O'Keefe GAD; Rao NA
Indian J Ophthalmol; 2022 Apr; 70(4):1121-1129. PubMed ID: 35325997
[TBL] [Abstract][Full Text] [Related]
59. Clinical manifestations and treatment outcomes of syphilitic uveitis in HIV-negative patients in China: A retrospective case study.
Zhu J; Jiang Y; Shi Y; Zheng B; Xu Z; Jia W
Medicine (Baltimore); 2017 Oct; 96(43):e8376. PubMed ID: 29069031
[TBL] [Abstract][Full Text] [Related]
60. [Ocular sarcoidosis: What the internist should know?].
Sève P; Kodjikian L; Jamilloux Y
Rev Med Interne; 2018 Sep; 39(9):728-737. PubMed ID: 29037464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
